Comment on difference in approach to genderspecific cancers using MRS and MRSI

This author is struck by the wealth of studies using in vivo MRS and MRSI for prostate cancer with noteworthy improvements in diagnostic accuracy (see Chapter 9), and the dearth, and in the case of endometrial cancer total absence, of publications applying MRS and particularly MRSI to gynecological cancers, as reviewed in the present chapter. We are hopeful that the benefits of molecular imaging through magnetic resonance will soon be made available with the aim of further improving diagnostics of these gynecologic cancers.


[1] R.F. Ozols, P.E. Schwartz, P.J. Eifel, Ovarian cancer, fallopian tube carcinoma and peritoneal carcinoma, in: V.T. de Vita, S. Hellman, S.A. Rosenberg, Cancer Principles & Practice of Oncology 6th Edition, Lippincott Williams & Wilkins, Philadelphia, 2001, p. 1597-1632.

[2] I.B. Runnebaum, E. Stickeler, Epidemiological and molecular aspects of ovarian cancer, J. Cancer Res. Clin. Oncol. 127, 73-79 (2001).

[3] R.C. Young, Gynecologic Malignancies, in: E Braunwald, A. Fauci, D.L. Kasper, S.L. Hauser, D.L. Longo, J.L. Jameson, Harrison's Principles of Internal Medicine, 15th Edition, McGraw-Hill, New York, 2001, p. 620-625.

[4] D. Gertig, D. Hunter, Ovarian cancer, in: H-O. Adami, D. Hunter, D. Trichopoulos, Textbook of Cancer Epidemiology, Oxford University Press, Oxford, 2002, p. 378-399.

[5] S.A. Funt, L.E. Hann, Detection and characterization of adnexal masses, Radiol. Clin. N. Am. 40, 591-608 (2002).

[6] A. Venn, D. Healy, R. McLachlan, Cancer risks associated with the diagnosis of infertility,

BestPract. Res. Clin. Obstet. Gyn. 17, 343-367 (2003).

[7] T.L. Marx, A.E. Mehta, Polycystic ovary syndrome; pathogenesis and treatment over the short and long term, Cleveland. Clin. J. Med. 70, 31-33, 36-41 (2003).

[8] K. Vasama-Neuvonen, E. Pukkala, H. Paakkulainen, P. Mutanen, E. Weiderpass, P. Boffetta, N. Shen, T. Kauppinen, H. Vainio, T. Partanen, Ovarian cancer and occupational exposures in Finland, Am.J. Indust. Med. 36, 83-89 (1999).

[9] N. Shen, E. Weiderpass, A. Antilla, M.S. Goldberg, K. Vasama-Neuvonen, P. Boffetta, H. Vainio, T. Partanen, Epidemiology of occupational and environmental risk factors related to ovarian cancer, Scand J. Work Environ Health 24, 175-182 (1998).

[10] S.A. Petralia, M. Desemeci, E.E. Adams, S.H. Zahm, Cancer mortality among women employed in health care occupations in 24 U.S. states, 1984-1993, Am. J. Indust. Med. 36, 159-165 (1999).

[11] S. Koifman, R.J. Koifman, A. Meyer, Human reproductive system disturbances and pesticide exposure in Brazil, Cad. Saude Publica 18, 435-445 (2002).

[12] J. Dich, S.H. Zahm, A. Hanberg, H.O. Adami, Pesticides and cancer, Cancer Causes & Control 8, 420-443 (1997).

[13] T. Shields, G. Gridley, T. Moradi, J. Adami, N. Plato, M. Dosemeci, Occupational exposures and the risk of ovarian cancer in Sweden, Am. J. Indust. Med. 42, 200-213 (2002).

[14] H. Langseth, A. Andersen, Cancer incidence among women in the Norwegian pulp and paper industry, Am J. Indust. Med. 36, 108-113 (1999).

[15] M.A. Bulbulyan, S. A. Ilychova, S.H. Zahm, S.V. Astashevsky, D.G. Zaridge, Cancer mortality among women in the Russian printing industry, Am. J. Indust. Med. 36, 166-171 (1999).

[16] D.S. Heller, R.E. Gordon, C. Westhoff, S. Gerber, Asbestos exposure and ovarian fiber burden, Am. J. Indust. Med. 29, 435-439 (1996).

[17] F.V. Coakley, Staging ovarian cancer: role of imaging, Radiol. Clin. NAm. 40, 609-636 (2002).

[18] R.R. Barakat, H. Hricak, What do we expect from imaging? Radiol. Clin. N. Am. 40, 521-526 (2002).

[19] A.K. Sood, J.I. Sorosky, M.S. Gelder, R.E. Buller, B. Anderson, E.J. Wilkinson, J.A. Benda, L.S. Morgan, Primary ovarian sarcoma Analysis of prognostic variables and the role of surgical cytoreduction, Cancer 82, 1731-1737 (1998).

[20] L. Cohen, Should transvaginal ultrasound be performed at annual examination in asymptomatic women? Int. J. Fertil. 48, 150-153 (2003)

[21] S.W. Cho, S.G. Cho, J.H. Lee, H-J Kim, M.H. Lim, J.H. Kim, C.H. Suh, In-vivo proton magnetic resonance spectroscopy in adnexal lesions, Korean J. Radiol. 3, 105-112 (2002).

[22] C. Anderiesz, M.A. Quinn, Screening for ovarian cancer, Med. J. Aust. 178, 655-656 (2003).

[23] F. Alexander-Sefre, U. Menon, I.J. Jacobs, Ovarian cancer screening, Hospital Med. 63, 210213 (2002).

[24] P.J. Paley, Ovarian cancer screening; are we making any progress? Curr. Opin. Oncol. 13, 399-402 (2001).

[25] K. Togashi, MR imaging of the ovaries: normal appearance and benign disease, Radiol. Clin. N. Am. 41, 799-811 (2003).

[26] G.E. Sarty, E.J. Kendall, J. Loewy, A. Dhir, O.A. Olatunbosun, R.A. Pierson, Magnetic resonance diffusion imaging of ovarian masses: a first experience with 12 cases, MAGMA 16, 182193 (2004).

[27] T. Okada, M. Harada, K. Matsuzaki, H. Nishitani, T. Aono, Evaluation of female intrapelvic tumors by clinical proton MR spectroscopy, J. Magn. Reson. Imaging 13, 912-917 (2001).

[28] I.C. Smith, D.E. Blandford, Diagnosis of cancer in humans by *H NMR of tissue biopsies,

[29] J.C. Wallace, G.P. Raaphorst, R.L. Somorjai, C.E. Ng, M. Fung Kee Fung, M. Senterman, I.C. Smith, Classification of 1H MR spectra of biopsies from untreated and recurrent ovarian cancer using linear discriminant analysis, Magn. Reson. Med. 38, 569-576 (1997).

[30] E.A. Boss, S.H. Moolenaar, L.F.A.G. Massuger, H. Boonstra, U.F.H. Engelke, J.G.N. de Jong, R.A. Wevers, High-resolution proton nuclear magnetic resonance spectroscopy of ovarian cyst fluid, NMR Biomed. 13, 297-305 (2000).

[31] L.F.A.G. Massuger, P.B.J. van Vierzen, U. Engelke, et al., *H-magnetic resonance spectroscopy. A new technique to discriminate benign from malignant ovarian tumors, Cancer 82, 1726-1730 (1998).

[32]. S. Stuver, H-O. Adami, in: H-O. Adami, D. Hunter, D. Trichopoulos, Textbook of Cancer Epidemiology, Oxford University Press, Oxford, 2002, p. 340-358.

[33] D.A. Savitz, K.W. Andrews, L.A. Brinton, Occupation and cervical cancer, J. Occup. Environ. Med. 37, 357-361 (1995).

[34] C.E. Mountford, W.B. Mackinnon, P. Russell, A. Rutter, E.J. Delikatny, Human cancers detected by proton MRS and chemical shift imaging ex vivo, Anticancer Res. 16, 1521-1532 (1996).

[35] J.R. Allen, R.W. Prost, O.W. Griffith, S.J. Erickson, B.A. Erickson, In vivo proton (H1) magnetic resonance spectroscopy for cervical carcinoma, Am. J. Clin. Oncol. 24, 522-529 (2001).

[36] J.H. Lee, K.S. Cho, Y.M. Kim, S.T. Kim, C.W. Mun, J.H. Na, J.E. Mok, T.H. Lim, Localized in vivo 1H nuclear MR spectroscopy for evaluation of human uterine cervical carcinoma. Am. J.

Roentgenol. 170, 1279-1282 (1998).

[37] C.E. Mountford, E.J. Delikatny, M. Dyne, K.T. Holmes, W.B. Mackinnon, R. Ford, J.C. Hunter, I.D. Truskett, P. Russell, Uterine cervical punch biopsy specimens can be analyzed by 1H

[38] E.J. Delikatny, P. Russell, J.C. Hunter, R. Hancock, K.H. Atkinson, C. van Haaften-Day, C.E. Mountford, Proton MR and human cervical neoplasia: ex vivo spectroscopy allows distinction of invasive carcinoma of the cervix from carcinoma in situ and other preinvasive lesions, Radiology 188, 791-796 (1993).

[39] B. Sitter, T. Bathen, B. Hagen, C. Arentz, F.E. Skjeldestad, I.S. Gribbestad, Cervical cancer tissue characterized by high-resolution magic angle spinning MR spectroscopy, MAGMA 16, 174181 (2004).

[40] I. Persson, H-O. Adami, Endometrial Cancer, in: H-O. Adami, D. Hunter, D. Trichopoulos,

Textbook of Cancer Epidemiology, Oxford University Press, Oxford, 2002, p. p. 359-377.

[41] T.W. Burke, P.J. Eifel, F.M. Muggia, Cancers of the uterine body, in: V.T. de Vita, S. Hellman, S.A. Rosenberg, Cancer Principles & Practice of Oncology 6th Edition, Lippincott Williams & Wilkins, Philadelphia, 2001, p. 1573-1594.

[42] S.R. Goldstein, Controversy about uterine effects and safety of SERMs: the sage continues,

[43] G. Robertson, Screening for endometrial cancer, Med. J. Australia 178, 657-659 (2003).

[44] S.M. Ascher, C. Reinhold, Imaging of cancer of the endometrium, Radiol. Clin. N. Am. 40, 563-576 (2002).

[45] C. Reinhold, I. Khalili, Postmenopausal bleeding: value of imaging, Radiol. Clin. N. Am. 40, 527-562 (2002)

[46] E. Weiderpass, E. Pukkala, K. Vasama-Neuvonen, T. Kauppinen, H. Vainio, H. Paakkulainen, P. Boffeta, T. Partanen, Occupational exposures and cancers of the endometrium and cervix uteri in Finland, Am. J. Indust. Med. 39, 572-580 (2001).

[47] U.G. Ahlborg, L. Lipworth, L. Titus-Ernstoff, C.C. Hsieh, A. Hanberg, J. Baron, Trichopoulos, H.O. Adami, Organochlorine compounds in relation to breast cancer, endometrial cancer and endometriosis: an assessment of the biological and epidemiological evidence, Crit. Rev. Toxicol. 25, 463-531 (1995).

[48] M. Mints, Idiopathic menorrhagia, Studies of angiogenesis and surgical therapy, Doctoral dissertation, Karolinska Institutet, Stockholm 2003.

[49] A.E. Li, D.A. Bluemke, Magnetic resonance imaging in: de Vita, S. Hellman, S.A. Rosenberg, Cancer Principles & Practice of Oncology 6th Edition, Lippincott Williams & Wilkins, Philadelphia, 2001, p. p. 669-679.

[50] S. Taieb, L. Ceugnart, E. Leblanc, A. Chevalier, V. Cabaret, D. Querleu, MR imaging of endometrial carcinoma: role and limits, Bull. Cancer 89, 963-968 (2002).

[51] K. Kinkel, Y. Kaji, K.K. Yu, M.R. Segal, Y. Lu, C.B. Powell, H. Hricak, Radiologic staging in patients with endometrial cancer: a meta-analysis, Radiology 212, 711-718 (1999).

[52] J. Schneider, M. Centeno, F. Säez, J. Genollä, A. Ruibal, Preoperative CA-125, CA 19-9 and nuclear magnetic resonance in endometrial carcinoma: correlation with surgical stage, Tumor Biol. 20, 25-29 (1999).

[53] T. Belhocine, C. De Barsy, R. Hustinx, J. Willems-Foidart, Usefulness of (18) F-FDG PET in the post-therapy surveillance of endometrial carcinoma. Eur. J. Nucl. Med. Molecular Imaging 29, 1132-1139 (2002).

[54] T. Jobo, T. Arai, R. Sato, H. Kuramoto, Clinicopathologic relevance of asymptomatic endometrial carcinoma, Acta Cytologica 47, 611-615 (2003).

[55] S. Ciatto, S. Cecchini, G. Gervasi, A. Landini, M. Zappa, E. Crocetti, Association of endometrial thickness assessed at trans-vaginal ultrasonography to endometrial cancer in postmenopausal women asymptomatic or with abnormal uterine bleeding, Radiol. Med. 104, 437442 (2002).

[56] J.L. Griffin, J.C.M. Pole, J.K. Nicholson, P.L. Carmichael, Cellular environment of metabolites and a metabolic study of tamoxifen endometrial cells using gradient high resolution magic angle spinning *H NMR spectroscopy, Biochim. Biophys. Acta. 1619, 151-158 (2003).

Natural Cures For Menopause

Natural Cures For Menopause

Are Menopause Symptoms Playing Havoc With Your Health and Relationships? Are you tired of the mood swings, dryness, hair loss and wrinkles that come with the change of life? Do you want to do something about it but are wary of taking the estrogen or antidepressants usually prescribed for menopause symptoms?

Get My Free Ebook

Post a comment